TITLE

Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability

AUTHOR(S)
Singh, Satish; Luisi, Donna; Pak, Roger
PUB. DATE
November 2015
SOURCE
Pharmaceutical Research;Nov2015, Vol. 32 Issue 11, p3541
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The convergence of advanced understanding of biology with chemistry has led to a resurgence in the development of antibody-drug conjugates (ADCs), especially with two recent product approvals. Design and development of ADCs requires the synergistic combination of the monoclonal antibody, the linker and the payload. Advances in antibody science has enabled identification and generation of high affinity, highly selective, humanized or human antibodies for a given target. Novel linker technologies have been synthesized and highly potent cytotoxic drug payloads have been created. As the first generation of ADCs utilizing lysine and cysteine chemistries moves through the clinic and into commercialization, second generation ADCs involving site specific conjugation technologies are being evaluated and tested. The latter aim to be better characterized and controlled, with wider therapeutic indices as well as improved pharmacokinetic-pharmacodynamic (PK-PD) profiles. ADCs offer some interesting physicochemical properties, due to conjugation itself, and to the (often) hydrophobic payloads that must be considered during their CMC development. New analytical methodologies are required for the ADCs, supplementing those used for the antibody itself. Regulatory filings will be a combination of small molecule and biologics. The regulators have put forth some broad principles but this landscape is still evolving.
ACCESSION #
110202854

 

Related Articles

  • Current ADC Linker Chemistry. Jain, Nareshkumar; Smith, Sean; Ghone, Sanjeevani; Tomczuk, Bruce // Pharmaceutical Research;Nov2015, Vol. 32 Issue 11, p3526 

    The list of ADCs in the clinic continues to grow, bolstered by the success of first two marketed ADCs: ADCETRIS® and Kadcyla®. Currently, there are 40 ADCs in various phases of clinical development. However, only 34 of these have published their structures. Of the 34 disclosed structures,...

  • Preclinical Dose-Formulation Stability. Smith, Amy; Whitsel, Melissa // Pharmaceutical Technology;Jun2012, Vol. 36 Issue 6, p60 

    The article focuses on the assessment of formulation, storage, and dosing conditions as part of designing adequate dose-formulation stability protocols. It states that assessment of preclinical dose formulation stability is completed by comparing the potency values obtained at different times....

  • Getting to the Core. Davis, Mindy I.; Simeonov, Anton; Lea, Wendy; Parker, Christian; Auld, Doug // Assay & Drug Development Technologies;May2014, Vol. 12 Issue 4, p197 

    The article presents abstracts on drug development topics which include three dimensional screening for the identification of copmpounds that target cells in dormant tumor spheroid regions, site-specific antibody drug conjugates, and sequence-based design of oligonucleotides to target microRNA.

  • Formulation, development and evaluation of injectable formulation of Aspirin. Patel, Rakesh P.; Patel, Kaushal P.; Modi, Kushal A.; Pathak, Chirayu J. // Drugs & Therapy Studies;2013, Vol. 3 Issue 1, p6 

    The objective of this study was to develop and manufacture a stable parenteral formulation for Aspirin, a non steroidal anti-inflammatory agent. The solubility and stability of the drug was determined. Solubility studies suggested that Aspirin exhibited poor aqueous solubility but showed...

  • Assessment of Physical Stability of an Antibody Drug Conjugate by Higher Order Structure Analysis: Impact of Thiol- Maleimide Chemistry. Guo, Jianxin; Kumar, Sandeep; Prashad, Amarnauth; Starkey, Jason; Singh, Satish // Pharmaceutical Research;Jul2014, Vol. 31 Issue 7, p1710 

    Purpose: To provide a systematic biophysical approach towards a better understanding of impact of conjugation chemistry on higher order structure and physical stability of an antibody drug conjugate (ADC). Methods: ADC was prepared using thiol-maleimide chemistry. Physical stabilities of ADC and...

  • PEG-interferon conjugates: Effects of length and structure of linker. Sabar, Muhammad Farooq; Kausar, Samra; Zafar, Ahmad Usman; Shahid, Mariam // Pakistan Journal of Pharmaceutical Sciences;Mar2013, Vol. 26 Issue 2, p425 

    Di-branched (Y-shaped) polyethylene glycols (PEGs) are considered more effective than linear molecules to enhance the efficacy of the conjugated drug. In the present study interferon α-2a was conjugated with three different 40 KDa di-branched PEGs. The results of this study show that length...

  • Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Lyon, Robert P; Bovee, Tim D; Doronina, Svetlana O; Burke, Patrick J; Hunter, Joshua H; Neff-LaFord, Haley D; Jonas, Mechthild; Anderson, Martha E; Setter, Jocelyn R; Senter, Peter D // Nature Biotechnology;Jul2015, Vol. 33 Issue 7, p733 

    The in vitro potency of antibody-drug conjugates (ADCs) increases with the drug-to-antibody ratio (DAR); however, ADC plasma clearance also increases with DAR, reducing exposure and in vivo efficacy. Here we show that accelerated clearance arises from ADC hydrophobicity, which can be modulated...

  • Marine Antibody-Drug Conjugates: Design Strategies and Research Progress. Yu-Jie Wang; Yu-Yan Li; Xiao-Yu Liu; Xiao-Ling Lu; Xin Cao; Bing-Hua Jiao // Marine Drugs;Jan2017, Vol. 15 Issue 1, p18 

    Antibody-drug conjugates (ADCs), constructed with monoclonal antibodies (mAbs), linkers, and natural cytotoxins, are innovative drugs developed for oncotherapy. Owing to the distinctive advantages of both chemotherapy drugs and antibody drugs, ADCs have obtained enormous success during the past...

  • Drug Carriers in Pharmaceutical Design: Promises and Progress. Dutta, Ranjna C. // Current Pharmaceutical Design;Mar2007, Vol. 13 Issue 7, p761 

    Ever since pure molecular entities have been adapted as drug, varied manifestations other than elimination of infections are frequently been acknowledged as side effects. Contemporary drug research focuses on these issues besides developing new molecules for the restoration of unnatural...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics